At a glance
ClinicalIndex Comparison Record- ✓Advanced or recurrent malignancies with failed systemic standard therapy or disease progression
- ✓Age >18 years old
- ✓At least one imaging measurable lesion
- ✓Expected survival ≥3 months
- ✕No neoantigens detected in sequencing data
- ✕History of bone marrow or stem cell transplantation
- ✕Enrolled in other therapeutic clinical trials
- ✕Active bacterial or fungal infections
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Individualized Tumor Neoantigen Peptide Vaccine in Combination with Unusual Immune Stimulating Radiotherapy in Refractory Solid Tumors (iNATURE) - a Phase II Randomized and Crossover Study
In Brief
A Phase 2 clinical trial evaluating Placebo + conventional treatment including radiotherapy and Radiation: Radiation Therapy；Biological: Personalized tumor peptide vaccine for Advanced Tumors. Currently recruiting, targeting 154 participants across 2 sites.
Signals
Detailed Summary
In this study, the investigators provide an individualized tumor neoantigen peptide vaccine in combination with radiotherapy to patients with advanced malignant solid tumors. The investigators observe the post-treatment tumor burden status, the immune response induced by immune preparations, and the prolongation of patient survival time, aiming to evaluate the effectiveness and safety of the individualized tumor neoantigen peptide vaccine in combination with radiotherapy
Study Details
Timeline
Interventions
Placebo + conventional treatment including radiotherapy
The peptide vaccine treatment will take 5 months as a treatment course until the treatment suspension event as stipulated in the plan occurred.